You just read:

New Data Shows STELARA® (ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Adult Patients With Moderately To Severely Active Crohn's Disease

News provided by

Janssen Biotech, Inc.

17 Feb, 2017, 08:00 ET